According to the April 13 issue of the Journal of the National Cancer Institute, whether or not first-line platinum based chemotherapy can benefit advanced-stage ovarian cancer patients can now potentially be established by using a DNA repair pathway-f…
A study led by Oxford University researchers, shows that taller women are more likely to develop ovarian cancer. Their work is part of a large worldwide study published in the journal PLoS Medicine this week and aims to define the factors which may ca…
A new analysis of published and unpublished studies concludes that risk for ovarian cancer is associated with increasing height. It also finds that among women who have never used hormone therapy for the menopause, the risk for developing the diseas…
Survival rates for cancer patients may be improved by treatment in specialised cancer centres, according to Cochrane researchers. In a review of recent studies, they found that women diagnosed with gynaecological cancer lived longer when treated in spe…
According to a study published in the journal Radiology, researchers from Cancer Research UK’s Cambridge Experimental Cancer Medicine Center at the University of Cambridge, have determined that the best method to monitor how women with late-stage ovari…
Scientists at Dana-Farber Cancer Institute have identified a subtype of ovarian cancer able to build its own blood vessels, suggesting that such tumors might be especially susceptible to “anti-angiogenic” drugs that block blood vessel formation. In a s…
Ovarian cancer is a major cause of death worldwide. Approximately 25,000 women will be diagnosed with ovarian cancer this year and 15,000 women will die from it in the United States alone. The novel anti-cancer drug diindolylmethane (DIM) has been show…
A study published January 13 in the Journal of the National Cancer Institute reveals that in the UK and the U.S., symptom indices used to identify individuals with symptoms connected with ovarian cancer who may need additional screening is on the rise,…
Treating ovarian cancer with the drug bevacizumab (“Avastin”) delays the disease and may also improve survival, show the results of an international clinical trial co-led by Drs. Amit Oza of the Princess Margaret Cancer Program, University Health Netwo…
Roche announced today that its product known as Avastin (bevacizumab) has been approved by the European Union for treatment of ovarian cancer. When used in combination with standard chemotherapy (carboplatin and paclitaxel) it will be part of a front-l…
